Navigation Links
Clarient Joins the HistoRx® Clinical Trials Network: First Commercial Lab to Provide Aqua® Technology for Clinical Trials
Date:10/24/2011

BRANFORD, Conn., Oct. 24, 2011 /PRNewswire/ -- Clarient, a GE Healthcare company, and HistoRx® , Inc., have signed a definitive agreement to provide pharma services using AQUA® technology to their growing lists of pharma clients.  By implementing HistoRx's AQUA technology in Clarient's CLIA laboratory, the two companies will apply their complementary capabilities to serve pharma companies' growing need for biomarker analysis in clinical trials. Use of tissue biomarkers to characterize a patient's tumor is becoming a crucial element of personalized cancer care.  AQUA technology is an automated, quantitative IHC testing method that enables standardized precision measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.

"HistoRx has helped numerous pharma clients with key development-phase decisions in the preclinical and translational medicine areas, harnessing the power of protein biomarkers to advance drug development," said Dick Carroll, Ph.D., Vice President of Clinical Research. "Now that AQUA technology is sought by drug developers for clinical trial support, raising the prospect of launching companion diagnostics based on these studies, expanding the network to include a commercial lab like Clarient gives more choices to study sponsors."

AQUA technology is increasingly used for high-precision evaluation of tissue biomarkers to formulate and test clinical hypotheses, particularly those centered on providing robust patient selection criteria for a given therapeutic in clinical trials.  The HistoRx Clinical Trials Network (HCTN) was initiated in response to significant interest from clinical research sponsors to have AQUA technology services available in a CLIA lab setting; HCTN members are the only sites approved and certified to perform AQUA analysis supporting clinical trials.  For the past five years pharmaceutical companies and oncology cooperative groups, and the researchers and clinicians involved in drug discovery, preclinical research and clinical development at those institutions, have used HistoRx Pharma Services to generate crucial information about their drug candidates, the metabolic pathways they affect, and the patient subgroups most likely to benefit from them.  The insights generated through AQUA technology and HistoRx Pharma Services provide compelling results with clear value in clinical programs, enabling pharmaceutical and biotech companies to use them for prospective analysis of patients in late-stage trials.  The HCTN, though centered on AQUA technology, has expanded its menu of offerings to include additional analysis technologies for use in clinical trials.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care and is the leader in quantitative immunohistochemistry.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA technology.  AQUA technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
2. Clarient Acquires Applied Genomics, Inc.
3. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
4. Clarient Announces CFO Transition Plan
5. GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.
6. Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test
7. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
8. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
9. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
10. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
11. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Create ... Abstract users can distort and manipulate three-dimensional shapes with ease all within ... ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April ... enthusiasm for Botox and lip injections, which she underwent in order to feel more ... Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Coast Dental ... 16, 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck ... for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet ...
Breaking Medicine News(10 mins):